Why the study?
Do new systemic drugs improve outcomes in patients with advanced soft tissue sarcoma who cannot receive anthracycline-based chemotherapy?
Do new systemic drugs improve outcomes in patients with advanced soft tissue sarcoma who cannot receive anthracycline-based chemotherapy?
New systemic drugs may be considered as first-line treatment for advanced soft tissue sarcoma patients who cannot tolerate anthracycline-based chemotherapy.
Answers are grounded in this paper and cite their sources.
Supports considering new agents for anthracycline-intolerant advanced STS; leaves open need for confirmatory trials.
New drugs may be beneficial for patients with advanced STS. When patients cannot receive anthracycline-based chemotherapy because of a high risk of side effects, we believe that the aforementioned drugs may be administered as the first-line treatment.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: